These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 1906003

  • 1. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
    Gross AS, Mikus G, Fischer C, Eichelbaum M.
    Eur J Clin Pharmacol; 1991; 40(2):155-62. PubMed ID: 1906003
    [Abstract] [Full Text] [Related]

  • 2. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
    Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M.
    Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
    [Abstract] [Full Text] [Related]

  • 3. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M.
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [Abstract] [Full Text] [Related]

  • 4. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS, Phillips AC, Rieutord A, Shenfield GM.
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [Abstract] [Full Text] [Related]

  • 5. Altered flecainide disposition in healthy volunteers taking quinine.
    Munafo A, Reymond-Michel G, Biollaz J.
    Eur J Clin Pharmacol; 1990 Apr; 38(3):269-73. PubMed ID: 2111245
    [Abstract] [Full Text] [Related]

  • 6. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F.
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [Abstract] [Full Text] [Related]

  • 7. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F, Vandamme N, Libersa C, Lhermitte M.
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [Abstract] [Full Text] [Related]

  • 8. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
    Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.
    Eur J Clin Pharmacol; 1993 Oct; 44(4):349-55. PubMed ID: 8513845
    [Abstract] [Full Text] [Related]

  • 9. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
    Jonkers RE, Koopmans RP, Portier EJ, van Boxtel CJ.
    J Pharmacol Exp Ther; 1991 Mar; 256(3):959-66. PubMed ID: 1848636
    [Abstract] [Full Text] [Related]

  • 10. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A, Gangji D, Derenne F, Jeanniot JP, Douchamps J.
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography.
    Doki K, Homma M, Kuga K, Watanabe S, Yamaguchi I, Kohda Y.
    J Pharm Biomed Anal; 2004 Sep 03; 35(5):1307-12. PubMed ID: 15336377
    [Abstract] [Full Text] [Related]

  • 12. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF.
    Pain; 1993 Jun 03; 53(3):335-339. PubMed ID: 8351162
    [Abstract] [Full Text] [Related]

  • 13. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y, Taga J, Ishizaki T, Ishikawa K.
    Br J Clin Pharmacol; 1990 Jan 03; 29(1):111-5. PubMed ID: 2297455
    [Abstract] [Full Text] [Related]

  • 14. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
    Lledó P, Abrams SM, Johnston A, Patel M, Pearson RM, Turner P.
    Eur J Clin Pharmacol; 1993 Jan 03; 44(1):63-7. PubMed ID: 8436157
    [Abstract] [Full Text] [Related]

  • 15. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M, Bertilsson L, Säwe J.
    Br J Clin Pharmacol; 1983 Mar 03; 15(3):317-21. PubMed ID: 6849767
    [Abstract] [Full Text] [Related]

  • 16. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF.
    Br J Clin Pharmacol; 1985 Dec 03; 20(6):555-66. PubMed ID: 2868742
    [Abstract] [Full Text] [Related]

  • 17. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS, Tucker GT, Woods HF.
    Clin Pharmacokinet; 1986 Dec 03; 11(1):1-17. PubMed ID: 2868819
    [Abstract] [Full Text] [Related]

  • 18. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK, Brøsen K, Hansen MG, Gram LF.
    Clin Pharmacol Ther; 1994 May 03; 55(5):518-27. PubMed ID: 8181196
    [Abstract] [Full Text] [Related]

  • 19. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H.
    Eur J Clin Pharmacol; 1992 May 03; 43(4):399-403. PubMed ID: 1451720
    [Abstract] [Full Text] [Related]

  • 20. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep 03; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.